Wendy Johnson is Chief Operating Officer of Reneo Pharmaceuticals, where she brings more than 30 years of experience in drug development, venture capital, licensing, strategy and corporate development. Prior to joining Reneo, Wendy was interim Chief Operating Officer and board member of AmpliPhi Bioscience (now Armata Pharmaceuticals). Wendy serves on the board of MorphoSys AG, a publicly held biotechnology company.
Wendy previously served on the investment team at ProQuest Investments and was president and CEO of Aires Pharmaceuticals, acquired by Mast Therapeutics. She also served as senior vice president of corporate development at Salmedix until its acquisition by Cephalon/Teva, and held executive roles at WomenFirst Healthcare, Selective Genetics and Cytel. Earlier in her career, she was assistant director of the Center for Devices and Radiological Health at the U.S. Food and Drug Administration. Wendy holds an M.B.A. from Loyola University, an M.S. in clinical microbiology from the Hahnemann Medical School and a B.S. in microbiology from the University of Maryland.